2018
DOI: 10.1002/jbt.22202
|View full text |Cite
|
Sign up to set email alerts
|

Caveolin‐1 contributes to anoikis resistance in human gastric cancer SGC‐7901 cells via regulating Src‐dependent EGFR‐ITGB1 signaling

Abstract: Anoikis resistance is considered to be an essential prerequisite of tumor metastasis and which is an important mechanism in the metastatic process of gastric cancer (GC). Caveolin-1 (CAV-1), a protein component of caveolae, has been reported to regulate several cancer cell behaviors including anoikis resistance. However, the role of CAV-1 in the acquisition of anoikis resistance in GC cells has never been explored. In this study, we investigated the promoting effect of CAV-1 on anchorage-independent growth and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
17
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(17 citation statements)
references
References 22 publications
0
17
0
Order By: Relevance
“…Indeed, CAV1 is reported to increase resistance to anoikis, which may be related to Cav1's role in neuroprotection. 65 , 66 Because the changed proteins were not significantly enriched in immune functions or pathways with this analysis, we cannot rule out the possibility that the immune effects of Cav1 KO may be indirect and due to alterations in the structure of the plasma membrane. This may, in fact, reconcile why some studies observe a pro- or anti-inflammatory effect, because a change in membrane dynamics could affect both.…”
Section: Resultsmentioning
confidence: 95%
“…Indeed, CAV1 is reported to increase resistance to anoikis, which may be related to Cav1's role in neuroprotection. 65 , 66 Because the changed proteins were not significantly enriched in immune functions or pathways with this analysis, we cannot rule out the possibility that the immune effects of Cav1 KO may be indirect and due to alterations in the structure of the plasma membrane. This may, in fact, reconcile why some studies observe a pro- or anti-inflammatory effect, because a change in membrane dynamics could affect both.…”
Section: Resultsmentioning
confidence: 95%
“…Many of these shared PPIs (e.g., EGF/ epidermal growth factor, SRC/neuronal proto-oncogene tyrosine-protein kinase, BCAR1/breast cancer anti-estrogen resistance protein 1) are also associated with anoikis (programmed cell death upon detachment from the extracellular matrix). Indeed, CAV1 has been reported to increase resistance to anoikis, which may be related to Cav1's role in neuroprotection (45,46). But because the changed proteins were not significantly enriched in immune functions or pathways, we cannot rule out the possibility that the immune effects of Cav1 KO may be indirect and due to alterations in the structure of the plasma membrane.…”
Section: Immunomodulatory Traf3 Protein Is Highly Expressed In Retinamentioning
confidence: 91%
“…The expression of CAV1 is higher in cancer compared to benign tissue and correlates with poor prognosis [127]. The overexpression of CAV1 is associated with increased cell survival, anchorageindependent growth, and epithelial-mesenchymal transition, migration, invasion, and resistance to anti-neoplastic drugs [38,94,111,127,176].…”
Section: Cav1 As a Tumor Suppressor Or Promotermentioning
confidence: 99%
“…Additional evidence places CAV1 at mitochondria-ER interphase sites (localizing CAV1 indirectly to mitochondria), referred to as mitochondria-associated ER membranes (MAMs), as well as lysosomal, peroxisomal, and exosomal membranes, as will be discussed in this review Src in focal adhesions [50]. In metastatic gastric cancer cells, CAV1 promotes resistance to anoikis in a Src-dependent manner by activation of the EGFR/integrin βI, PI3K/pAkt, and MEK/ERK signaling pathways [176]. In addition, in hepatocellular cancer cell lines, CAV1 is required for the induction of survival via the TGF-β/EGFR/pAkt signaling pathway [111].…”
Section: Cav1 As a Tumor Suppressor Or Promotermentioning
confidence: 99%